Is Syncom Formul. overvalued or undervalued?

As of 26 September 2025, the valuation grade for Syncom Formul. has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently overvalued based on its financial metrics. Key ratios include a PE Ratio of 29.09, an EV to EBITDA of 26.26, and a PEG Ratio of 0.29, which suggests that despite the high PE, the growth expectations are not being met relative to the price.
When compared to its peers, Syncom Formul. stands out as very expensive, especially against Sun Pharma with a PE of 33.18 and Divi's Lab at a staggering 65.51. In contrast, more attractively valued peers like Cipla and Dr. Reddy's Labs have PE ratios of 22.45 and 18.4, respectively. The stock has underperformed in the year-to-date period, showing a decline of 11.00% compared to a 2.93% increase in the Sensex, reinforcing the notion that Syncom Formul. is not just overvalued but also struggling relative to broader market trends.